## Supplemental Table 1. Comprehensive baseline patient characteristics

<table>
<thead>
<tr>
<th>Number of Patients (%) (N=1150)</th>
<th>Age</th>
<th>ECOG PS</th>
<th>Histology</th>
<th>Prior Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0-70 Yr (n=883)</td>
<td>≥70 Yr (n=267)</td>
<td>0 (n=460)</td>
<td>1-2 (n=685)</td>
</tr>
<tr>
<td>Male</td>
<td>858 (75)</td>
<td>653 (74)</td>
<td>205 (77)</td>
<td>363 (79)</td>
</tr>
<tr>
<td>Female</td>
<td>292 (25)</td>
<td>230 (26)</td>
<td>62 (23)</td>
<td>97 (21)</td>
</tr>
<tr>
<td>Median age, years (range)</td>
<td>62 (18-84)</td>
<td>58 (18-69)</td>
<td>74 (70-84)</td>
<td>61 (18-84)</td>
</tr>
<tr>
<td>Age &lt;70 years</td>
<td>883 (77)</td>
<td>512 (75)</td>
<td>46 (87)</td>
<td>85 (76)</td>
</tr>
<tr>
<td>Age ≥70 years</td>
<td>267 (23)</td>
<td>173 (25)</td>
<td>7 (13)</td>
<td>27 (24)</td>
</tr>
<tr>
<td>ECOG PS 0</td>
<td>460 (40)</td>
<td>366 (41)</td>
<td>94 (35)</td>
<td>377 (41)</td>
</tr>
<tr>
<td>ECOG PS 1</td>
<td>516 (45)</td>
<td>374 (42)</td>
<td>142 (53)</td>
<td>404 (44)</td>
</tr>
<tr>
<td>ECOG PS 2</td>
<td>169 (15)</td>
<td>138 (16)</td>
<td>31 (12)</td>
<td>123 (14)</td>
</tr>
<tr>
<td>ECOG PS missing</td>
<td>5 (&lt;1)</td>
<td>5 (&lt;1)</td>
<td>0</td>
<td>5 (&lt;1)</td>
</tr>
<tr>
<td>Clear-cell only</td>
<td>909 (79)</td>
<td>688 (78)</td>
<td>221 (83)</td>
<td>377 (82)</td>
</tr>
<tr>
<td>Clear-cell with sarcomatoid features*</td>
<td>53 (5)</td>
<td>46 (5)</td>
<td>7 (3)</td>
<td>10 (2)</td>
</tr>
<tr>
<td>Clear-cell with papillary features</td>
<td>112 (10)</td>
<td>85 (10)</td>
<td>27 (10)</td>
<td>46 (10)</td>
</tr>
<tr>
<td>Clear-cell with other histologic types</td>
<td>66 (6)</td>
<td>58 (7)</td>
<td>8 (3)</td>
<td>25 (5)</td>
</tr>
<tr>
<td>Other</td>
<td>10 (&lt;1)</td>
<td>6 (&lt;1)</td>
<td>4 (1)</td>
<td>2 (&lt;1)</td>
</tr>
<tr>
<td>Lung mets</td>
<td>841 (73)</td>
<td>651 (74)</td>
<td>190 (71)</td>
<td>326 (71)</td>
</tr>
<tr>
<td>Bone mets</td>
<td>370 (32)</td>
<td>303 (34)</td>
<td>67 (25)</td>
<td>103 (22)</td>
</tr>
<tr>
<td>Liver mets</td>
<td>318 (28)</td>
<td>252 (29)</td>
<td>66 (25)</td>
<td>110 (24)</td>
</tr>
<tr>
<td>Brain mets</td>
<td>28 (2)</td>
<td>25 (3)</td>
<td>3 (1)</td>
<td>11 (2)</td>
</tr>
<tr>
<td>1 tumor site</td>
<td>272 (24)</td>
<td>194 (22)</td>
<td>78 (29)</td>
<td>123 (27)</td>
</tr>
<tr>
<td>2 tumor sites</td>
<td>338 (29)</td>
<td>251 (28)</td>
<td>87 (33)</td>
<td>154 (33)</td>
</tr>
<tr>
<td>≥3 tumor sites</td>
<td>539 (47)</td>
<td>437 (49)</td>
<td>102 (36)</td>
<td>182 (40)</td>
</tr>
<tr>
<td>Missing no. tumor sites</td>
<td>1 (&lt;1)</td>
<td>1 (&lt;1)</td>
<td>0</td>
<td>1 (&lt;1)</td>
</tr>
<tr>
<td>Prior systemic anticancer therapy</td>
<td>815 (71)</td>
<td>643 (73)</td>
<td>172 (64)</td>
<td>340 (74)</td>
</tr>
<tr>
<td>Prior cytokine therapy</td>
<td>785 (67)</td>
<td>602 (68)</td>
<td>163 (61)</td>
<td>324 (70)</td>
</tr>
<tr>
<td>Prior nephrectomy</td>
<td>1020 (89)</td>
<td>784 (89)</td>
<td>236 (88)</td>
<td>421 (92)</td>
</tr>
</tbody>
</table>
### Supplemental Table 1. Comprehensive baseline patient characteristics (continued)

<table>
<thead>
<tr>
<th>Table 1.1</th>
<th>Without Nephrectomy (n=130)</th>
<th>With Nephrectomy (n=1020)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prior Nephrectomy</strong></td>
<td><strong>Lung (n=841)</strong></td>
<td><strong>Liver (n=318)</strong></td>
</tr>
<tr>
<td>Male</td>
<td>93 (72)</td>
<td>765 (75)</td>
</tr>
<tr>
<td>Female</td>
<td>37 (28)</td>
<td>255 (25)</td>
</tr>
<tr>
<td><strong>Median age, years (range)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>61 (18-84)</td>
<td>62 (18-84)</td>
<td>62 (18-84)</td>
</tr>
<tr>
<td><strong>Age &lt;70 years</strong></td>
<td>99 (76)</td>
<td>236 (24)</td>
</tr>
<tr>
<td>Age ≥70 years</td>
<td>31 (24)</td>
<td>236 (23)</td>
</tr>
<tr>
<td><strong>ECOG PS 0</strong></td>
<td>39 (30)</td>
<td>421 (41)</td>
</tr>
<tr>
<td><strong>ECOG PS 1</strong></td>
<td>55 (42)</td>
<td>461 (45)</td>
</tr>
<tr>
<td><strong>ECOG PS 2</strong></td>
<td>35 (27)</td>
<td>134 (13)</td>
</tr>
<tr>
<td><strong>ECOG PS missing</strong></td>
<td>1 (&lt;1)</td>
<td>4 (&lt;1)</td>
</tr>
<tr>
<td><strong>Clear-cell only</strong></td>
<td>111 (85)</td>
<td>798 (78)</td>
</tr>
<tr>
<td><strong>Clear-cell with sarcomatoid features</strong></td>
<td>2 (2)</td>
<td>51 (5)</td>
</tr>
<tr>
<td><strong>Clear-cell with papillary features</strong></td>
<td>7 (5)</td>
<td>105 (10)</td>
</tr>
<tr>
<td><strong>Clear-cell with other histologic types</strong></td>
<td>2 (2)</td>
<td>64 (6)</td>
</tr>
<tr>
<td><strong>Other histology</strong></td>
<td>8 (6)</td>
<td>2 (&lt;1)</td>
</tr>
<tr>
<td><strong>Lung mets</strong></td>
<td>94 (72)</td>
<td>747 (73)</td>
</tr>
<tr>
<td><strong>Bone mets</strong></td>
<td>46 (35)</td>
<td>324 (32)</td>
</tr>
<tr>
<td><strong>Liver mets</strong></td>
<td>40 (31)</td>
<td>278 (27)</td>
</tr>
<tr>
<td><strong>Brain mets</strong></td>
<td>5 (4)</td>
<td>23 (20)</td>
</tr>
<tr>
<td><strong>1 tumor site</strong></td>
<td>3 (2)</td>
<td>269 (26)</td>
</tr>
<tr>
<td><strong>2 tumor sites</strong></td>
<td>26 (20)</td>
<td>312 (31)</td>
</tr>
<tr>
<td><strong>≥3 tumor sites</strong></td>
<td>101 (78)</td>
<td>438 (43)</td>
</tr>
<tr>
<td><strong>Missing no. tumor sites</strong></td>
<td>0</td>
<td>1 (&lt;1)</td>
</tr>
<tr>
<td><strong>Prior systemic anticancer therapy</strong></td>
<td>57 (44)</td>
<td>708 (69)</td>
</tr>
<tr>
<td><strong>Prior cytokine therapy</strong></td>
<td>57 (44)</td>
<td>708 (69)</td>
</tr>
<tr>
<td><strong>Prior nephrectomy</strong></td>
<td>747 (89)</td>
<td>278 (87)</td>
</tr>
</tbody>
</table>